Original from: 360DX
Exact Sciences reported after the close of the market on Tuesday that its first quarter revenues rose 21 percent year over year.
For the three months ended March 31, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $486.6 million, up from $402.1 million a year earlier, beating the average Wall Street estimate of $461.7 million.
Excluding the company's COVID-19 testing revenues, which were down 15 percent at $27.4 million, Exact said it's Q4 revenue increased 24 percent year over year.
Precision oncology revenues, which include global sales of the Oncotype DX test and Oncomap therapy selection products, were up 18 percent at $152.6 million compared to $129.4 million in Q1 2021. The company's screening revenues ¡ª mostly from Cologuard testing with some contribution from Exact's recent acquisition, PreventionGenetics ¡ª rose 28 percent to $306.5 million from $240.3 million.
Exact attributed this growth to improved sales productivity, Cologuard rescreens, and use of the test by the 45-49 age group.
Exact's Q1 net loss grew to $180.9 million, or $1.04 per share, from $31.2 million, or $.18 per share, in the year-ago period. Analysts had expected a loss of $1.07 per share.
The company's R&D costs for the quarter shrank about 12 percent to $102.2 million from $115.6 million in Q1 2021, while its SG&A expenses dropped 11 percent to $402 million from $453.8 million.
Exact ended the quarter with $189.8 million in cash and cash equivalents and $627.2 million in marketable securities.
The company revised its full-year 2022 revenue guidance to a new range of between $1.985 billion and $2.032 billion from a previous range of $1.975 billion to $2.027 billion.
The new range assumes screening revenues of between $1.35 billion and $1.37 billion and precision oncology revenue between $595 million and $610 million, with between $40 million and $50 million in COVID-19 testing revenues.
